Matthew Foehr Sells 16,000 Shares of Viking Therapeutics (NASDAQ:VKTX) Stock

Viking Therapeutics, Inc. (NASDAQ:VKTX) Director Matthew Foehr sold 16,000 shares of the firm’s stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $35.11, for a total value of $561,760.00. Following the sale, the director directly owned 132,036 shares in the company, valued at approximately $4,635,783.96. The trade was a 10.81% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Viking Therapeutics Stock Performance

Shares of Viking Therapeutics stock opened at $32.30 on Wednesday. The company has a market capitalization of $3.65 billion, a PE ratio of -15.24 and a beta of 0.71. The company has a 50-day simple moving average of $36.38 and a two-hundred day simple moving average of $32.40. Viking Therapeutics, Inc. has a one year low of $18.92 and a one year high of $43.15.

Viking Therapeutics (NASDAQ:VKTX) last released its quarterly earnings results on Wednesday, October 22nd. The biotechnology company reported ($0.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.14). During the same quarter last year, the company posted ($0.22) EPS. The firm’s quarterly revenue was up .0% compared to the same quarter last year. On average, equities analysts predict that Viking Therapeutics, Inc. will post -1.56 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently commented on the company. Cantor Fitzgerald set a $105.00 price objective on Viking Therapeutics in a report on Thursday, October 23rd. BTIG Research reiterated a “buy” rating and issued a $125.00 price target on shares of Viking Therapeutics in a research note on Monday, September 22nd. Morgan Stanley raised their price target on Viking Therapeutics from $98.00 to $102.00 and gave the stock an “overweight” rating in a report on Thursday, October 23rd. Zacks Research upgraded shares of Viking Therapeutics from a “strong sell” rating to a “hold” rating in a report on Wednesday, November 19th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Viking Therapeutics from $80.00 to $75.00 and set an “overweight” rating for the company in a research report on Friday, October 24th. Three equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $87.14.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of VKTX. GAMMA Investing LLC boosted its position in Viking Therapeutics by 71.0% in the fourth quarter. GAMMA Investing LLC now owns 1,195 shares of the biotechnology company’s stock valued at $42,000 after buying an additional 496 shares during the last quarter. PVG Asset Management Corp raised its position in Viking Therapeutics by 18.7% during the 3rd quarter. PVG Asset Management Corp now owns 13,364 shares of the biotechnology company’s stock worth $351,000 after buying an additional 2,106 shares during the last quarter. FNY Investment Advisers LLC lifted its stake in Viking Therapeutics by 45.5% during the 3rd quarter. FNY Investment Advisers LLC now owns 11,628 shares of the biotechnology company’s stock valued at $305,000 after acquiring an additional 3,636 shares during the period. IFP Advisors Inc boosted its holdings in shares of Viking Therapeutics by 12.7% in the 3rd quarter. IFP Advisors Inc now owns 58,496 shares of the biotechnology company’s stock valued at $1,651,000 after acquiring an additional 6,571 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB boosted its holdings in shares of Viking Therapeutics by 42.9% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 10,000 shares of the biotechnology company’s stock valued at $263,000 after acquiring an additional 3,000 shares during the last quarter. 76.03% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Viking Therapeutics

Here are the key news stories impacting Viking Therapeutics this week:

• Positive Sentiment: CEO Brian Lian is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference — the presentation (management commentary, clinical updates or Q&A) could provide new data or clarity on the pipeline and drive re-rating if news is constructive. Read More.
• Neutral Sentiment: Market note: coverage highlighted a recent sharp close-to-close decline, providing context for sentiment but not new company-specific catalysts. Read More.
• Negative Sentiment: CEO sale: Brian Lian sold 233,409 shares at an average ~$32.96 (≈$7.69M), lowering his stake ~8.5% — a material, same-day sale by the CEO can signal insider liquidity needs and weighs on investor sentiment. Read More.
• Negative Sentiment: CFO sale: Greg Zante sold 57,661 shares at ~\$32.90 (≈\$1.90M), cutting his position ~23% — adds to concentrated insider selling. Read More.
• Negative Sentiment: COO sale: Marianna Mancini sold 57,661 shares at ~\$32.98 (≈\$1.90M), reducing her stake ~12% — simultaneous sales by multiple senior officers amplify negative interpretation. Read More.
• Negative Sentiment: Director sale: Matthew Foehr sold 16,000 shares at \$35.11 (≈\$562k), trimming his holding ~10.8% — adds to the cluster of insider liquidity events. Read More.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. Headquartered in San Diego, California, the company’s pipeline leverages small-molecule approaches to target hormone signaling pathways implicated in conditions such as non‐alcoholic steatohepatitis (NASH), dyslipidemia, type 2 diabetes and muscle wasting disorders.

The company’s lead programs include VK2809, a thyroid hormone receptor‐beta agonist designed to reduce liver fat and improve lipid profiles in patients with NASH and dyslipidemia, and VK5211, a selective androgen receptor modulator (SARM) aimed at enhancing muscle mass and function in individuals with muscle wasting conditions.